Compare Adaptive Biotechnologies Corp (ADPT) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs DigitalOcean Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while DigitalOcean Holdings Inc trades at $134.22 (market cap $14.21B). The key difference: DigitalOcean Holdings Inc is far larger — about 3.5× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, DigitalOcean Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | DOCN | |
|---|---|---|
Market Cap | $4.04B | $14.21B |
Sector | Health | Technology |
52-Week High | $25.45 | $181.29 |
52-Week Low | $12.30 | $29.99 |
Enterprise Value | $4.10B | $14.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
DigitalOcean (DOCN) trades at $133.47, up 2.88% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with 29% revenue growth driven by AI-native cloud demand. Profitability remains robust with a 23.27% net income margin, though valuation ratios like P/E of 54.94 are elevated. Recent news highlights AI infrastructure growth and a CEO focus on profitable expansion.
Outlook is positive with a consensus price target of $173.71 implying 30% upside, supported by accelerating revenue and AI tailwinds. Risks include high debt levels, competitive cloud market pressures, and reliance on sustained AI demand. The stock offers growth exposure but requires monitoring of execution and valuation sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
